We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Apollon Formularies plc | AQSE:APOL | Aquis Stock Exchange | Ordinary Share | IM00BJ0LRD77 | Ordinary shares |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.095 | 0.07 | 0.12 | 0.095 | 0.085 | 0.085 | 0.00 | 08:03:30 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2022 to Apr 2024
TIDMAPOL
RNS Number : 3413I
Apollon Formularies plc
02 December 2022
2 December 2022
Apollon Formularies Plc
Notice of AGM
Apollon Formularies plc (AQSE: APOL, "Apollon" or the "Company"), announces that notice of its Annual General Meeting ('AGM') has been posted to shareholders, and will shortly be available at the Company website on https://www.apollon.org.uk/ . The AGM will be held on 30 December 2022 at 10am, at 48 Warwick Street, London, W1B 5AW.
The directors of the Company accept responsibility for the contents of this announcement.
ENDS
For additional information, please visit www.apollon.org.uk or contact:
Apollon Formularies
Tel: +44 771 198 0221 Stene Jacobs stene@apollon.org.uk
Peterhouse Capital Limited (Corporate Adviser)
Tel: +44 207 220 9795 Guy Miller gm@peterhousecapital.com
Blytheweigh (Financial PR/IR-London)
Tel: +44 207 138 3204 Tim Blythe/Megan Ray apollon@blytheray.com
About Apollon and Apollon Jamaica
Apollon Formularies plc is an international medical cannabis and medicinal mushroom pharmaceutical company headquartered in the United Kingdom. Apollon Formularies Jamaica Limited is a pharmaceutical company incorporated and operating in the Commonwealth of Jamaica since 2016. Apollon Jamaica is licensed by the Jamaican government's Cannabis Licensing Authority (CLA) to cultivate (R&D), perform research and development, process, and sell medical cannabis therapeutic products that include legal medical cannabis to treat various illnesses under medical supervision.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NEXFLFFDFELLIIF
(END) Dow Jones Newswires
December 02, 2022 02:00 ET (07:00 GMT)
1 Year Apollon Formularies Chart |
1 Month Apollon Formularies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
